Figure 3. A heatmap of mean scores per type of guideline across stakeholder groups (green indicates higher acceptance, red lower)
A subgroup analysis (Figure 4) revealed that the Blood Products and Quality Working Parties have a lower acceptance level for comments overall. The results were similar to guidelines that are authored by multiple working parties. The Biosimilar Medicines and Pharmacokinetic Working Parties have been receptive towards comments from governmental authorities, but less so for others. The Biologics, Cardiovascular, Safety and Rheumatology/Immunology Working Parties do not reflect any trends with scores above or close to 1 for other stakeholders than government.